Searched for
ZYDUS WORLDWIDE
These large-, mid- and small-cap stocks can give more than 25% return in 1 year, according to analystsAs the old saying goes: Nothing can be ruled out on the street. Which means that one should be prepared for anything. Now, what is the prob...- Scanning cancer, up close & personal: A revolution is underway in cancer diagnosisA gene-based test called next-generation sequencing can identify precise mutations, which can then be treated with targeted therapies. Sinc...
- Zydus Lifesciences shares fall 2% as firm acquires US-based Assertio Holdings for $166 millionZydus Lifesciences' shares dipped 2% after completing the $166.4 million acquisition of US-based Assertio Holdings Inc. The deal, finalized...
- Zydus Lifesciences completes acquisition of AssertioThe company has successfully completed the cash tender offer, through wholly-owned subsidiary, Zara Merger Sub Inc, for all the outstanding...
- Wockhardt secures US FDA approval for antibiotic ZaynichWockhardt's novel antibiotic, Zaynich (cefepime and zidebactam), has received US FDA approval for complicated urinary tract infections. Thi...
- For both the compulsive trader and careful investor: 25 stocks to watch if risk appetite returns; some with upside potential, some notIf the price of crude oil softens, Indian equities may again see a risk-on phase. Tariff concerns are no longer the central issue; the larg...
- Zydus Lifesciences shares jump 6% on buyback buzz; co announces $166 mn Assertio acquisitionZydus Lifesciences shares witnessed a spike on Thursday after the company said its board will meet on May 19 to consider a share buyback. T...
- Zydus to buy Assertio for $166.4 millionZydus is acquiring US-based Assertio Holdings for $166.40 million to bolster its specialty oncology presence in the US. The deal, structure...
- Zydus Lifesciences acquires US pharma firm Assertio for $166 millionIn a bold move that positions Zydus at the forefront of the U.S. specialty oncology market, the Indian drug manufacturer has secured a $166...
- Stock picks of the week: 5 stocks with consistent score improvement and upside potential of up to 29%In the current phase of market volatility, the only solace to be derived is from market history. And history tells us that, just like good ...
- Bain Capital sole contender for Vitabiotics buyBain Capital has emerged as the frontrunner to acquire Vitabiotics, as rival bidders TPG Capital and EQT exit the process, potentially lowe...
- Zydus Lifesciences gets USFDA nod for 2 generic drugsThe tentative approval granted by the US Food and Drug Administration (USFDA) to the company's arm Zydus Worldwide DMCC to market Valbenazi...
- Zydus gets USFDA nod to market generic antifungal medicationEfinaconazole is an antifungal used for the topical treatment of Onychomycosis of the toenails due to Trichophyton rubrum and Trichophyton ...
- Zydus Cadila gets US Food and Drug Administration nod for diabetes medicationOn October 31, 2020, Zydus had filed a new drug application (NDA) with the USFDA seeking approval to market Sitagliptin base 25, 50 and 100...
- Zydus Cadila launches new product for COPD patients in IndiaDrug firm Zydus Cadila on Thursday said it is launching pressurized metered dose inhaler for patients suffering from Chronic Obstructive Pu...
- India's Zydus Cadila to make Gilead's potential COVID-19 drug remdesivirZydus, listed as Cadila Healthcare, joins other Indian pharmaceutical companies Cipla Ltd, Jubilant Sciences Ltd and privately held Hetero ...
- Zydus gets final nod from USFDA for anti-bacterial drugZydus Cadila is a global pharmaceutical company that develops, manufactures and markets a broad range of healthcare therapies. The group em...
- Cadila Healthcare settles patent litigation related to Livalo tabletsThe company and its subsidiary have finalised an agreement with Kowa Company and Nissan Chemical Industries to settle all outstanding paten...
- Zydus Healthcare buys 2 ANDAs from TevaThe company said these ANDAs have been acquired by its 100 per cent subsidiary, Zydus Worldwide DMCC and will be financed through the group...
- Zydus ties up with US-based research centre NIAD to develop vaccineThe Group employs over 16,500 people worldwide, including over 1,600 scientists in R&D. Cadila Healthcare is part of Zydus Group.
Load More
